Cx501    (DrugBank: CX501)

1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa2

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00987142
(ClinicalTrials.gov)
December 200629/9/2009Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys BullosaA Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis BullosaEPIDERMOLYSIS BULLOSADrug: CX501;Device: Occlusive non adherent dressingTigenix S.A.U.NULLCompletedN/AN/AAll12Phase 2Spain
2EUCTR2005-002329-30-ES
(EUCTR)
09/08/200615/03/2010ENSAYO CLINICO COMPARATIVO, ABIERTO, MULTICENTRICO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA NUEVA TERAPIA CON PIEL QUIMÉRICA CULTIVADA PARA EL TRATAMIENTO DE LAS LESIONES CUTÁNEAS DE LOS PACIENTES CON EPIDERMOLISIS BULLOSAENSAYO CLINICO COMPARATIVO, ABIERTO, MULTICENTRICO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA NUEVA TERAPIA CON PIEL QUIMÉRICA CULTIVADA PARA EL TRATAMIENTO DE LAS LESIONES CUTÁNEAS DE LOS PACIENTES CON EPIDERMOLISIS BULLOSA Epidermolisis Bullosa distrófica recesiva con sindactilia cutánea severa
MedDRA version: 9.1;Level: LLT;Classification code 10014989;Term: Epidermolysis bullosa
Product Code: CX501CELLERIX, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Spain